| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
S1P1 (IC50 = 1.88 nM)
Etrasimod arginine primarily targets S1P1 receptors, acting as a potent full agonist. By activating S1P1 receptors, it induces lymphocyte sequestration in lymph nodes, reducing circulating lymphocytes and their infiltration into inflamed tissues. It also has partial agonist activity at S1P4. This leads to anti-inflammatory and immunomodulatory effects. |
|---|---|
| ln Vitro |
Etrasimod arginine/APD-334 is a structurally novel, selective, functional antagonist of S1P1. In CHO cells expressing HA tagged S1P1, APD334 is found to have an IC50 value of 1.88 nM. Moderate agonism at human S1P4 and S1P5 is observed but is reduced relative to S1P1, both in terms of potency and efficacy. APD334 is devoid of any agonism or antagonism at human S1P2 and S1P3. APD334 achieves good central exposure following oral dosing and possesses a favorable pharmacokinetic profile in multiple preclinical species. S1P1 activity is maintained in mice (EC50=0.44 nM), rats (EC50=0.32 nM), dogs (EC50=0.34 nM) and monkeys (EC50=0.32 nM)[1].
In vitro, Etrasimod arginine is a potent full agonist at S1P1 receptors with EC50 values in the sub-nanomolar range. It induces S1P1 receptor internalization and inhibits lymphocyte egress. The compound is soluble in aqueous solutions and can be quantified by LC-MS. |
| ln Vivo |
Etrasimod arginine/APD-334 has a relatively low systemic clearance (<4% of hepatic blood flow) and high Cmax across all species. In both dog and monkey a significant decrease in volume of distribution (Vss) is observed relative to rodent. Oral bioavailability is in the range of 40–100%, and the terminal phase half-life varied from 6 h in monkey, to as long as 29 h in dog. Rat and monkey t1/2 values for siponimod (another S1P1 modulator currently in human trials) have been disclosed and are 6 and 19 h, respectively[1]. Rats: APD334 induced effects on blood lymphopenia are determined in male Sprague-Dawley rats. Briefly, male rats are given a 0 (vehicle only), 0.03 (mice only), 0.1, 0.3 or 1 mg/kg oral dose of APD334 formulated in 0.5% methylcellulose (MC) in water. Rat blood samples are collected at 0, 1, 3, 5, 8, 16, 24, 32, 48 and 72 hours post-dose[1]. Mice: APD334 induced effects on blood lymphopenia are determined in male BALB/c mice. Briefly, male mice are given a 0 (vehicle only), 0.03 (mice only), 0.1, 0.3 or 1 mg/kg oral dose of APD334 formulated in 0.5% methylcellulose (MC) in water. Mouse blood samples are taken at 0, 1, 3, 5, 8, 16, 24 and 32 hours post-dose[1]. In vivo, Etrasimod arginine reduces circulating lymphocytes and ameliorates inflammation in animal models of colitis and multiple sclerosis. It is orally active and well-absorbed. The compound is being investigated for ulcerative colitis and other autoimmune diseases. |
| Enzyme Assay |
For S1P receptor binding assays, membrane fractions from cells expressing S1P1 or S1P4 receptors are incubated with [32P]S1P in the presence of Etrasimod arginine at varying concentrations. Reactions are performed at 25°C for 60-120 minutes.
|
| Cell Assay |
For functional assays, cells expressing S1P1 receptors are treated with Etrasimod arginine, and GTPγS binding or cAMP inhibition is measured. For lymphocyte egress assays, animals are treated with the compound, and lymphocyte counts in blood and lymph nodes are measured.
|
| Animal Protocol |
Rats: Male Sprague-Dawley rats are used to assess the effects of APD334 on blood lymphopenia. Male rats are administered an oral dose of APD334 formulated in 0.5% methylcellulose (MC) in water at a rate of 0 mg/kg (vehicle only), 0.03 mg/kg (mice only), 0.1, 0.3, or 1 mg/kg. Samples of rat blood are taken 0, 1, 3, 5, 8, 16, 24, 32, 48, and 72 hours after the dose[1].
Mice: Male BALB/c mice are used to study the effects of APD334 on blood lymphopenia. In summary, APD334 is administered orally to male mice at doses of 0 (vehicle only), 0.03 (mice only), 0.1, 0.3, or 1 mg/kg when formulated in 0.5% methylcellulose (MC) in water. At 0, 1, 3, 5, 8, 16, 24, and 32 hours after administration, mouse blood samples are collected[1]. For in vivo studies, mice with experimental autoimmune encephalomyelitis (EAE) or colitis are administered Etrasimod arginine orally at doses ranging from 0.1-10 mg/kg daily. Disease severity is scored, and tissue histology is assessed. For pharmacokinetic studies, plasma levels of etrasimod are quantified by LC-MS/MS. |
| References | |
| Additional Infomation |
Etrasimod arginine salt is an organic ammonium salt composed of eztramod and an equimolar amount of L-arginine. It is a sphingosine-1-phosphate receptor modulator approved for the treatment of moderate to severe active ulcerative colitis in adults. It has anti-inflammatory, immunosuppressive, and sphingosine-1-phosphate receptor 1 antagonist effects. It contains one L-arginine (1+) and one eztramod (1-).
See also: Etrasimod (note moved to). Drug Indications Treatment of ulcerative colitis Treatment of Crohn's disease |
| Molecular Formula |
C32H40F3N5O5
|
|---|---|
| Molecular Weight |
631.69
|
| Exact Mass |
631.298
|
| Elemental Analysis |
C, 68.26; H, 5.73; F, 12.46; N, 3.06; O, 10.49
|
| CAS # |
1206123-97-8
|
| Related CAS # |
1206123-37-6;1206123-97-8 (arginine);
|
| PubChem CID |
44624336
|
| Appearance |
Typically exists as solid at room temperature
|
| tPSA |
190
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
45
|
| Complexity |
871
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CC[C@@H]5CC(=O)O)C(F)(F)F.C(C[C@@H](C(=O)O)N)CN=C(N)N
|
| InChi Key |
GVPVVOSNDUAUKM-BPGOJFKZSA-N
|
| InChi Code |
InChI=1S/C26H26F3NO3.C6H14N4O2/c27-26(28,29)22-11-15(5-8-19(22)16-3-1-2-4-16)14-33-18-7-10-23-21(13-18)20-9-6-17(12-24(31)32)25(20)30-237-4(5(11)12)2-1-3-10-6(8)9/h5,7-8,10-11,13,16-17,30H,1-4,6,9,12,14H2,(H,31,32)4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t17-4-/m10/s1
|
| Chemical Name |
L-Arginine, (3R)-7-((4-cyclopentyl-3-(trifluoromethyl)phenyl)methoxy)-1,2,3,4-tetrahydrocyclopent(b)indole-3-acetate (1
|
| Synonyms |
APD-334 L-Arginine APD334 APD 334 Etrasimod arginine; Velsipity
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5831 mL | 7.9153 mL | 15.8305 mL | |
| 5 mM | 0.3166 mL | 1.5831 mL | 3.1661 mL | |
| 10 mM | 0.1583 mL | 0.7915 mL | 1.5831 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
A Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis
CTID: NCT06294925
Phase:   Status: Recruiting
Date: 2024-10-28